News Feed Item

The Leukemia & Lymphoma Society Announces Recipients of The Screen to Lead Grant Program

Five Distinguished Researchers Receive First-Time Grant

WHITE PLAINS, N.Y., Jan. 16, 2014 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today is pleased to announce the researchers who will receive funding through The Screen to Lead program - a new grant program to support drug discovery specifically directed toward medicinal chemistry and/or drug target screening in blood cancers.  

LLS recognizes investigators' significant need for resources to develop small molecules into drug-like compounds suitable for preclinical proof-of-concept testing in cancer models.  The goal is to fill a gap in the drug development process in academic laboratories, with the potential that novel targeted therapies may eventually be evaluated and benefit patients.

"LLS funds research to advance more breakthrough therapies for cancer patients.  This funding support is specifically designed to advance promising compounds in the earliest stages of development," said Lee Greenberger, Ph.D., LLS chief scientific officer.  "It is critically important that leading scientists and researchers get financial resources to pursue innovative, novel approaches that can change the standard of care for patients with blood cancers."

The amounts of the grants awarded to these innovative researchers will vary and be determined on a case by case basis. The awardees are:

Li Chai, M.D. – Brigham and Women's, Boston
Chai will target SALL4 in the treatment of acute myeloid leukemia (AML).  SALL4 is a transcription factor – a protein that regulates genetic activity, and is abnormally expressed in most AML patient samples.  Chai's team has been testing a peptide that can block SALL4.  While peptides can be useful as tools, they have low stability in the body so the team is performing high throughput tests to identify other compounds with drug-like characteristics that might also be effective in blocking SALL4. The team has produced an assay, a laboratory test that enables researchers to examine thousands of compounds, that will be used by a contract research organization (CRO) to identify those that are effective against SALL4.

Michael Deininger, M.D., Ph.D. – Huntsman Cancer Institute, Salt Lake City
Signal Transducer and Activator of Transcription 3 (STAT3) is a protein involved in the regulation of cell growth and survival.  It is frequently super-activated in patients with certain cancers.  Deininger has developed assays to identify STAT3 inhibitors and through medicinal chemistry approaches, has generated more potent inhibitors.  The grant will assist him in his goal of making compounds more effective at inhibiting STAT3 at lower doses.  Promising compounds will be synthesized on a larger scale and will be tested in animal models of therapy-resistant chronic myeloid leukemia (CML) as well as in myelofibrosis (MF).  Since STAT3 is activated in a number of cancers, compounds developed may be useful beyond CML and MF.

Yali Dou, Ph.D. – University of Michigan
Epigenetics are small chemical modifications that alter gene activity without changing the DNA code of those genes.  Abnormal epigenetic changes are often associated with the growth of cancer cells.  A protein known as mixed-lineage leukemia protein (MLL) works with a host of other proteins to mediate such epigenetic alterations and is genetically altered in certain patients with AML resulting in a particularly poor prognosis for these patients.  Dou's team has developed an assay whereby purified MLL and its associated co-regulator proteins are mixed, and their epigenetic modifying activity can be quantitatively measured.  They will screen large libraries of compounds with drug-like characteristics in this assay, and determine which ones can inhibit the epigenetic modifying activity.  Positive hits in the screen will be used as lead compounds for improvement, which can then be tested in cancer models as antitumor agents.

Aaron Schimmer, M.D., Ph.D. – Princess Margaret Cancer Center/Ontario Cancer Institute
The proteasome is a machine in the cell that regulates the degradation of proteins in the cells, and is essential to getting rid of proteins no longer needed.  In addition, the proteasome is crucial to the normal cell signaling process required for growth and survival of the cell.  Certain cancer cells, such as those found in patients with multiple myeloma, have high levels of proteasome activity.  Thus, inhibiting the proteasome has been an effective anti-cancer therapy, as is the case of Velcade® in patients with multiple myeloma.  Velcade targets the proteasome in the cytoplasm.  Schimmer has recently shown that inhibiting the proteasome in the mitochondria (energy factory) has anti-tumor activity.  This is a novel approach to cancer therapy, and the identification of a drug specifically targeting the mitochondrial proteasome may lead to a first-in-class drug for treatment of patients with AML and potentially other cancers.

David Williams, M.D. – Children's Hospital Boston
The Rac proteins are required for cancer development in a number of systems.  Williams has explored the role of these proteins in CML, AML, and more recently, acute lymphocytic leukemia (ALL).  His team has shown that inhibition of Rac can lead to cancer cell death.  From previously LLS-funded research, compounds were identified that inhibit Rac and were tested as anti-cancer agents.  They successfully identified a number of lead compounds worthy of further refinement.  The purpose of this grant is to continue the project to use a medicinal chemistry approach to improve these compounds, potentially identifying lead compounds that may be candidates for clinical evaluation. 

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, multiple myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.  

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif
(914) 821-8958
[email protected]

SOURCE The Leukemia & Lymphoma Society

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The Internet of Things (IoT) promises to simplify and streamline our lives by automating routine tasks that distract us from our goals. This promise is based on the ubiquitous deployment of smart, connected devices that link everything from industrial control systems to automobiles to refrigerators. Unfortunately, comparatively few of the devices currently deployed have been developed with an eye toward security, and as the DDoS attacks of late October 2016 have demonstrated, this oversight can ...
Smart Cities are here to stay, but for their promise to be delivered, the data they produce must not be put in new siloes. In his session at @ThingsExpo, Mathias Herberts, Co-founder and CTO of Cityzen Data, will deep dive into best practices that will ensure a successful smart city journey.
President Obama recently announced the launch of a new national awareness campaign to "encourage more Americans to move beyond passwords – adding an extra layer of security like a fingerprint or codes sent to your cellphone." The shift from single passwords to multi-factor authentication couldn’t be timelier or more strategic. This session will focus on why passwords alone are no longer effective, and why the time to act is now. In his session at 19th Cloud Expo, Chris Webber, security strateg...
November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Penta Security is a leading vendor for data security solutions, including its encryption solution, D’Amo. By using FPE technology, D’Amo allows for the implementation of encryption technology to sensitive data fields without modification to schema in the database environment. With businesses having their data become increasingly more complicated in their mission-critical applications (such as ERP, CRM, HRM), continued ...
In the 21st century, security on the Internet has become one of the most important issues. We hear more and more about cyber-attacks on the websites of large corporations, banks and even small businesses. When online we’re concerned not only for our own safety but also our privacy. We have to know that hackers usually start their preparation by investigating the private information of admins – the habits, interests, visited websites and so on. On the other hand, our own security is in danger bec...
Two weeks ago (November 3-5), I attended the Cloud Expo Silicon Valley as a speaker, where I presented on the security and privacy due diligence requirements for cloud solutions. Cloud security is a topical issue for every CIO, CISO, and technology buyer. Decision-makers are always looking for insights on how to mitigate the security risks of implementing and using cloud solutions. Based on the presentation topics covered at the conference, as well as the general discussions heard between sessi...
In his general session at 18th Cloud Expo, Lee Atchison, Principal Cloud Architect and Advocate at New Relic, discussed cloud as a ‘better data center’ and how it adds new capacity (faster) and improves application availability (redundancy). The cloud is a ‘Dynamic Tool for Dynamic Apps’ and resource allocation is an integral part of your application architecture, so use only the resources you need and allocate /de-allocate resources on the fly.
SYS-CON Events announced today that Cloudbric, a leading website security provider, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Cloudbric is an elite full service website protection solution specifically designed for IT novices, entrepreneurs, and small and medium businesses. First launched in 2015, Cloudbric is based on the enterprise level Web Application Firewall by Penta Security Sys...
SYS-CON Events announced today that Impiger Technologies will exhibit in Booth #109 at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Impiger Technologies is a world-class, enterprise software product engineering company specializing in Mobile Application Development, Cloud Applications, Microsoft Technology Solutions, Web Technology and Telecom Services. Impiger Technologies helps enterprises improve busi...
Virgil consists of an open-source encryption library, which implements Cryptographic Message Syntax (CMS) and Elliptic Curve Integrated Encryption Scheme (ECIES) (including RSA schema), a Key Management API, and a cloud-based Key Management Service (Virgil Keys). The Virgil Keys Service consists of a public key service and a private key escrow service. 

SYS-CON Events announced today that Cemware will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Use MATLAB functions by just visiting website mathfreeon.com. MATLAB compatible, freely usable, online platform services. As of October 2016, 80,000 users from 180 countries are enjoying our platform service.
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Digitization is driving a fundamental change in society that is transforming the way businesses work with their customers, their supply chains and their people. Digital transformation leverages DevOps best practices, such as Agile Parallel Development, Continuous Delivery and Agile Operations to capitalize on opportunities and create competitive differentiation in the application economy. However, information security has been notably absent from the DevOps movement. Speed doesn’t have to negat...
SYS-CON Events announced today that eCube Systems, the leading provider of modern development tools and best practices for Continuous Integration on OpenVMS, will exhibit at SYS-CON's @DevOpsSummit at Cloud Expo New York, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. eCube Systems offers a family of middleware products and development tools that maximize return on technology investment by leveraging existing technical equity to meet evolving business needs. ...
SYS-CON Events announced today that MathFreeOn will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. MathFreeOn is Software as a Service (SaaS) used in Engineering and Math education. Write scripts and solve math problems online. MathFreeOn provides online courses for beginners or amateurs who have difficulties in writing scripts. In accordance with various mathematical topics, there are more tha...